{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:02:41Z","timestamp":1792202561958,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Developing regenerative therapies to restore kidney function in patients with progressive renal disease represents a major challenge for modern molecular nephrology. Kidney organoids, three-dimensional kidney-like structures, which can now be generated by the directed differentiation of human pluripotent stem cells, have emerged as a powerful tool to study kidney development, physiology, and mechanisms of renal disease in vitro. Ultimately, kidney organoids may serve as an experimental platform to unravel the pathomechanisms of renal fibrosis and to test regenerative treatment approaches targeting fibrotic kidney diseases. However, the fibrotic phenotype in kidney organoids and its utility as a disease model remain to be fully characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three-dimensional self-organizing kidney organoids containing nephrons and stromal cells were exposed to TGF-\u03b21 cytokine to induce fibrotic remodeling. Organoids were analyzed by RNA sequencing and histology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Activation of TGF-\u03b21 signaling in kidney organoids induced hallmarks of human kidney fibrosis, such as tubular atrophy, glomerulosclerosis, and interstitial fibrosis. RNA sequencing highlighted differential regulation of key pathways in kidney fibrosis: epithelial-to-mesenchymal transition, inflammation, metabolism, and JAK\/STAT signaling. We identified candidate mediators of kidney fibrosis such as the JAK-STAT downstream target PIM1. Inhibition of PIM1 with the small molecule AZD1208 attenuated fibrosis development in the organoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Kidney organoids are an amenable system for modeling kidney fibrosis and may guide therapeutic discovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-026-05030-4","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:44:58Z","timestamp":1777185898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Induction of fibrosis in human kidney organoids delineates mechanisms and therapeutic targets of fibrotic kidney disease"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-1506","authenticated-orcid":false,"given":"Markus C.","family":"Doeser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Raimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Beuke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Kilcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie F.","family":"Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.","family":"Klinkhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Boor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans R.","family":"Sch\u00f6ler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Pavenst\u00e4dt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"issue":"10075","key":"5030_CR1","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(16)32064-5.","journal-title":"Lancet"},{"key":"5030_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-981-13-8871-2_1","volume":"1165","author":"JC Lv","year":"2019","unstructured":"Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3\u201315. https:\/\/doi.org\/10.1007\/978-981-13-8871-2_1.","journal-title":"Adv Exp Med Biol"},{"key":"5030_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mam.2018.06.002","volume":"65","author":"S Djudjaj","year":"2019","unstructured":"Djudjaj S, Boor P. Cellular and molecular mechanisms of kidney fibrosis. Mol Aspects Med. 2019;65:16\u201336. https:\/\/doi.org\/10.1016\/j.mam.2018.06.002.","journal-title":"Mol Aspects Med"},{"issue":"2","key":"5030_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199\u2013210. https:\/\/doi.org\/10.1002\/path.2277.","journal-title":"J Pathol"},{"issue":"6","key":"5030_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-\u03b2: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325\u201338. https:\/\/doi.org\/10.1038\/nrneph.2016.48.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"5030_CR6","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1073\/pnas.90.5.1814","volume":"90","author":"T Yamamoto","year":"1993","unstructured":"Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993;90(5):1814\u20138. https:\/\/doi.org\/10.1073\/pnas.90.5.1814.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6282","key":"5030_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/346371a0","volume":"346","author":"WA Border","year":"1990","unstructured":"Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990;346(6282):371\u20134. https:\/\/doi.org\/10.1038\/346371a0.","journal-title":"Nature"},{"issue":"7","key":"5030_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/sj.ki.5001775","volume":"70","author":"JA Moon","year":"2006","unstructured":"Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 2006;70(7):1234\u201343. https:\/\/doi.org\/10.1038\/sj.ki.5001775.","journal-title":"Kidney Int"},{"key":"5030_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.matbio.2017.12.016","volume":"68\u201369","author":"AH Gy\u00f6rfi","year":"2018","unstructured":"Gy\u00f6rfi AH, Matei AE, Distler JHW. Targeting TGF-\u03b2 signaling for the treatment of fibrosis. Matrix Biol. 2018;68\u201369:8\u201327. https:\/\/doi.org\/10.1016\/j.matbio.2017.12.016.","journal-title":"Matrix Biol"},{"issue":"11","key":"5030_CR10","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","volume":"33","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Brosius FC 3rd, Adler SG, et al. JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrol Dial Transpl. 2018;33(11):1950\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfx377.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"5030_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.34067\/KID.0006492020","volume":"2","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Sudhini YR, Reiser J, Altintas MM. From infancy to fancy: a glimpse into the evolutionary journey of podocytes in culture. Kidney360. 2020;2(2):385\u201397. https:\/\/doi.org\/10.34067\/KID.0006492020.","journal-title":"Kidney360"},{"issue":"1\u20132","key":"5030_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ddmod.2010.08.002","volume":"7","author":"HC Yang","year":"2010","unstructured":"Yang HC, Zuo Y, Fogo AB. Models of chronic kidney disease. Drug Discov Today Dis Models. 2010;7(1\u20132):13\u20139. https:\/\/doi.org\/10.1016\/j.ddmod.2010.08.002.","journal-title":"Drug Discov Today Dis Models"},{"issue":"6194","key":"5030_CR13","doi-asserted-by":"publisher","first-page":"1247125","DOI":"10.1126\/science.1247125","volume":"345","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125. https:\/\/doi.org\/10.1126\/science.1247125.","journal-title":"Science"},{"key":"5030_CR14","doi-asserted-by":"publisher","first-page":"8715","DOI":"10.1038\/ncomms9715","volume":"6","author":"Freedman","year":"2015","unstructured":"Freedman BS, Brooks CR, Lam AQ, et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat Commun. 2015;6:8715. https:\/\/doi.org\/10.1038\/ncomms9715. Published 2015 Oct 23.","journal-title":"Nat Commun"},{"key":"5030_CR15","doi-asserted-by":"publisher","unstructured":"Takasato M, Er PX, Chiu HS et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis [published correction appears. Nature. 2015;526(7574):564\u2013568. https:\/\/doi.org\/10.1038\/nature15695","DOI":"10.1038\/nature15695"},{"issue":"3","key":"5030_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.stem.2019.06.009","volume":"25","author":"JH Low","year":"2019","unstructured":"Low JH, Li P, Chew EGY, et al. Generation of human PSC-derived kidney organoids with patterned nephron segments and a de novo vascular network. Cell Stem Cell. 2019;25(3):373\u2013e3879. https:\/\/doi.org\/10.1016\/j.stem.2019.06.009.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"5030_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.stemcr.2018.08.003","volume":"11","author":"S Tanigawa","year":"2018","unstructured":"Tanigawa S, Islam M, Sharmin S, et al. Organoids from nephrotic disease-derived iPSCs identify impaired NEPHRIN localization and slit diaphragm formation in kidney podocytes. Stem Cell Rep. 2018;11(3):727\u201340. https:\/\/doi.org\/10.1016\/j.stemcr.2018.08.003.","journal-title":"Stem Cell Rep"},{"issue":"11","key":"5030_CR18","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nbt.3392","volume":"33","author":"R Morizane","year":"2015","unstructured":"Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat Biotechnol. 2015;33(11):1193\u2013200. https:\/\/doi.org\/10.1038\/nbt.3392.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"5030_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.stem.2018.04.022","volume":"22","author":"SM Czerniecki","year":"2018","unstructured":"Czerniecki SM, Cruz NM, Harder JL, et al. High-throughput screening enhances kidney organoid differentiation from human pluripotent stem cells and enables automated multidimensional phenotyping. Cell Stem Cell. 2018;22(6):929\u2013e9404. https:\/\/doi.org\/10.1016\/j.stem.2018.04.022.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"5030_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2021.12.010","volume":"29","author":"J Jansen","year":"2022","unstructured":"Jansen J, Reimer KC, Nagai JS, et al. SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. Cell Stem Cell. 2022;29(2):217\u2013e2318. https:\/\/doi.org\/10.1016\/j.stem.2021.12.010.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"5030_CR21","doi-asserted-by":"publisher","first-page":"6496","DOI":"10.1038\/s41467-021-26596-y","volume":"12","author":"JOR Hernandez","year":"2021","unstructured":"Hernandez JOR, Wang X, Vazquez-Segoviano M, et al. A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo. Nat Commun. 2021;12(1):6496. https:\/\/doi.org\/10.1038\/s41467-021-26596-y. Published 2021 Nov 11.","journal-title":"Nat Commun"},{"issue":"6","key":"5030_CR22","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1681\/ASN.2017121283","volume":"29","author":"DR Lemos","year":"2018","unstructured":"Lemos DR, McMurdo M, Karaca G, et al. Interleukin-1\u03b2 activates a MYC-dependent metabolic switch in kidney stromal cells necessary for progressive tubulointerstitial fibrosis. J Am Soc Nephrol. 2018;29(6):1690\u2013705. https:\/\/doi.org\/10.1681\/ASN.2017121283.","journal-title":"J Am Soc Nephrol"},{"issue":"7841","key":"5030_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","volume":"589","author":"C Kuppe","year":"2021","unstructured":"Kuppe C, Ibrahim MM, Kranz J, et al. Decoding myofibroblast origins in human kidney fibrosis. Nature. 2021;589(7841):281\u20136. https:\/\/doi.org\/10.1038\/s41586-020-2941-1.","journal-title":"Nature"},{"issue":"6","key":"5030_CR24","doi-asserted-by":"publisher","first-page":"e51169","DOI":"10.15252\/embr.202051169","volume":"22","author":"L Li","year":"2021","unstructured":"Li L, Galichon P, Xiao X, et al. Orphan nuclear receptor COUP-TFII enhances myofibroblast glycolysis leading to kidney fibrosis. EMBO Rep. 2021;22(6):e51169. https:\/\/doi.org\/10.15252\/embr.202051169.","journal-title":"EMBO Rep"},{"issue":"1","key":"5030_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nprot.2016.170","volume":"12","author":"R Morizane","year":"2017","unstructured":"Morizane R, Bonventre JV. Generation of nephron progenitor cells and kidney organoids from human pluripotent stem cells. Nat Protoc. 2017;12(1):195\u2013207. https:\/\/doi.org\/10.1038\/nprot.2016.170.","journal-title":"Nat Protoc"},{"issue":"1","key":"5030_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s40478-019-0871-7","volume":"7","author":"G Gomez-Giro","year":"2019","unstructured":"Gomez-Giro G, Arias-Fuenzalida J, Jarazo J, et al. Synapse alterations precede neuronal damage and storage pathology in a human cerebral organoid model of CLN3-juvenile neuronal ceroid lipofuscinosis. Acta Neuropathol Commun. 2019;7(1):222. https:\/\/doi.org\/10.1186\/s40478-019-0871-7. Published 2019 Dec 30.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"5030_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ki.2010.158","volume":"78","author":"PY Chuang","year":"2010","unstructured":"Chuang PY, He JC. JAK\/STAT signaling in renal diseases. Kidney Int. 2010;78(3):231\u20134. https:\/\/doi.org\/10.1038\/ki.2010.158.","journal-title":"Kidney Int"},{"issue":"2","key":"5030_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2337\/db08-1328","volume":"58","author":"CC Berthier","year":"2009","unstructured":"Berthier CC, Zhang H, Schin M, et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes. 2009;58(2):469\u201377. https:\/\/doi.org\/10.2337\/db08-1328.","journal-title":"Diabetes"},{"issue":"3","key":"5030_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ki.2010.154","volume":"78","author":"M Pang","year":"2010","unstructured":"Pang M, Ma L, Gong R, et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 2010;78(3):257\u201368. https:\/\/doi.org\/10.1038\/ki.2010.154.","journal-title":"Kidney Int"},{"issue":"5","key":"5030_CR30","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1172\/JCI122462","volume":"130","author":"C Dees","year":"2020","unstructured":"Dees C, P\u00f6tter S, Zhang Y, et al. TGF-\u03b2-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. J Clin Invest. 2020;130(5):2347\u201363. https:\/\/doi.org\/10.1172\/JCI122462.","journal-title":"J Clin Invest"},{"issue":"8","key":"5030_CR31","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/bph.15013","volume":"177","author":"B Corden","year":"2020","unstructured":"Corden B, Adami E, Sweeney M, Schafer S, Cook SA. IL-11 in cardiac and renal fibrosis: Late to the party but a central player. Br J Pharmacol. 2020;177(8):1695\u2013708. https:\/\/doi.org\/10.1111\/bph.15013.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5030_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/03008207.2018.1500558","volume":"60","author":"L Stawski","year":"2019","unstructured":"Stawski L, Trojanowska M. Oncostatin M and its role in fibrosis. Connect Tissue Res. 2019;60(1):40\u20139. https:\/\/doi.org\/10.1080\/03008207.2018.1500558.","journal-title":"Connect Tissue Res"},{"key":"5030_CR33","doi-asserted-by":"publisher","first-page":"104312","DOI":"10.1016\/j.ebiom.2022.104312","volume":"86","author":"S Xu","year":"2022","unstructured":"Xu S, Yang X, Chen Q, et al. Leukemia inhibitory factor is a therapeutic target for renal interstitial fibrosis. EBioMedicine. 2022;86:104312. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104312.","journal-title":"EBioMedicine"},{"issue":"12","key":"5030_CR34","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1681\/ASN.2014070717","volume":"26","author":"J Yan","year":"2015","unstructured":"Yan J, Zhang Z, Yang J, Mitch WE, Wang Y. JAK3\/STAT6 stimulates bone marrow-derived fibroblast activation in renal fibrosis. J Am Soc Nephrol. 2015;26(12):3060\u201371. https:\/\/doi.org\/10.1681\/ASN.2014070717.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"5030_CR35","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41419-019-2085-0","volume":"10","author":"C Zheng","year":"2019","unstructured":"Zheng C, Huang L, Luo W, et al. Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice. Cell Death Dis. 2019;10(11):848. https:\/\/doi.org\/10.1038\/s41419-019-2085-0. Published 2019 Nov 7.","journal-title":"Cell Death Dis"},{"issue":"1","key":"5030_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrc2986","volume":"11","author":"MC Nawijn","year":"2011","unstructured":"Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11(1):23\u201334. https:\/\/doi.org\/10.1038\/nrc2986.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"5030_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/MPA.0b013e31823cdd10","volume":"41","author":"KM Block","year":"2012","unstructured":"Block KM, Hanke NT, Maine EA, Baker AF. IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas. 2012;41(5):773\u201381. https:\/\/doi.org\/10.1097\/MPA.0b013e31823cdd10.","journal-title":"Pancreas"},{"issue":"6","key":"5030_CR38","doi-asserted-by":"publisher","first-page":"e153672","DOI":"10.1172\/jci.insight.153672","volume":"7","author":"TX Pham","year":"2022","unstructured":"Pham TX, Lee J, Guan J, et al. Transcriptional analysis of lung fibroblasts identifies PIM1 signaling as a driver of aging-associated persistent fibrosis. JCI Insight. 2022;7(6):e153672. https:\/\/doi.org\/10.1172\/jci.insight.153672. Published 2022 Mar 22.","journal-title":"JCI Insight"},{"issue":"8","key":"5030_CR39","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/art.40863","volume":"71","author":"R Fu","year":"2019","unstructured":"Fu R, Xia Y, Li M, et al. Pim-1 as a Therapeutic Target in Lupus Nephritis. Arthritis Rheumatol. 2019;71(8):1308\u201318. https:\/\/doi.org\/10.1002\/art.40863.","journal-title":"Arthritis Rheumatol"},{"key":"5030_CR40","doi-asserted-by":"publisher","first-page":"109563","DOI":"10.1016\/j.intimp.2022.109563","volume":"114","author":"Y Luo","year":"2023","unstructured":"Luo Y, Zhu J, Zhao F, Shi L, Li Y, Wu X. PIM1 attenuates renal ischemia-reperfusion injury by inhibiting ASK1-JNK\/P38. Int Immunopharmacol. 2023;114:109563. https:\/\/doi.org\/10.1016\/j.intimp.2022.109563.","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"5030_CR41","doi-asserted-by":"publisher","first-page":"e0136994","DOI":"10.1371\/journal.pone.0136994","volume":"10","author":"S Nakagawa","year":"2015","unstructured":"Nakagawa S, Nishihara K, Miyata H, et al. Molecular markers of tubulointerstitial fibrosis and tubular cell damage in patients with chronic kidney disease. PLoS ONE. 2015;10(8):e0136994. https:\/\/doi.org\/10.1371\/journal.pone.0136994. Published 2015 Aug 28.","journal-title":"PLoS ONE"},{"issue":"5","key":"5030_CR42","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ajpath.2022.01.009","volume":"192","author":"AB Nunez-Nescolarde","year":"2022","unstructured":"Nunez-Nescolarde AB, Nikolic-Paterson DJ, Combes AN. Human kidney organoids and tubuloids as models of complex kidney disease. Am J Pathol. 2022;192(5):738\u201349. https:\/\/doi.org\/10.1016\/j.ajpath.2022.01.009.","journal-title":"Am J Pathol"},{"issue":"2","key":"5030_CR43","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.stemcr.2018.06.018","volume":"11","author":"A Przepiorski","year":"2018","unstructured":"Przepiorski A, Sander V, Tran T, et al. A simple bioreactor-based method to generate kidney organoids from pluripotent stem cells. Stem Cell Rep. 2018;11(2):470\u201384. https:\/\/doi.org\/10.1016\/j.stemcr.2018.06.018.","journal-title":"Stem Cell Rep"},{"issue":"1","key":"5030_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13287-022-02752-z","volume":"13","author":"A Przepiorski","year":"2022","unstructured":"Przepiorski A, Vanichapol T, Espiritu EB, et al. Modeling oxidative injury response in human kidney organoids. Stem Cell Res Ther. 2022;13(1):76. https:\/\/doi.org\/10.1186\/s13287-022-02752-z. Published 2022 Feb 21.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"5030_CR45","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.labinv.2024.100336","volume":"104","author":"X Yang","year":"2024","unstructured":"Yang X, Delsante M, Daneshpajouhnejad P, et al. Bile acid receptor agonist reverses transforming growth factor-\u03b21-mediated fibrogenesis in human induced pluripotent stem cells-derived kidney organoids. Lab Invest. 2024;104(5):100336. https:\/\/doi.org\/10.1016\/j.labinv.2024.100336.","journal-title":"Lab Invest"},{"key":"5030_CR46","doi-asserted-by":"crossref","unstructured":"Gupta N, Matsumoto T, Hiratsuka K et al. Modeling injury and repair in kidney organoids reveals that homologous recombination governs tubular intrinsic repair [published correction appears in Sci Transl Med. 2022;14(647):eadd0524. doi: 10.1126\/scitranslmed.add0524]. Sci Transl Med. 2022;14(634):eabj4772.","DOI":"10.1126\/scitranslmed.abj4772"},{"issue":"1","key":"5030_CR47","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/s42003-022-04264-1","volume":"5","author":"JL Davis","year":"2022","unstructured":"Davis JL, Kennedy C, Clerkin S, et al. Single-cell multiomics reveals the complexity of TGF\u03b2 signalling to chromatin in iPSC-derived kidney organoids. Commun Biol. 2022;5(1):1301. https:\/\/doi.org\/10.1038\/s42003-022-04264-1. Published 2022 Nov 27.","journal-title":"Commun Biol"},{"issue":"4","key":"5030_CR48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11154-008-9100-6","volume":"9","author":"FC Brosius","year":"2008","unstructured":"Brosius FC 3. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord. 2008;9(4):245\u201354. https:\/\/doi.org\/10.1007\/s11154-008-9100-6.","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"5030_CR49","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.2337\/diabetes.51.12.3505","volume":"51","author":"X Wang","year":"2002","unstructured":"Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB. Inhibition of the Jak\/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes. 2002;51(12):3505\u20139. https:\/\/doi.org\/10.2337\/diabetes.51.12.3505.","journal-title":"Diabetes"},{"key":"5030_CR50","doi-asserted-by":"publisher","first-page":"110969","DOI":"10.1016\/j.cellsig.2023.110969","volume":"113","author":"Y Li","year":"2024","unstructured":"Li Y, Shi L, Zhao F, et al. PIM1 attenuates cisplatin-induced AKI by inhibiting Drp1 activation. Cell Signal. 2024;113:110969. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110969.","journal-title":"Cell Signal"},{"key":"5030_CR51","doi-asserted-by":"publisher","unstructured":"Smyth LJ, Kilner J, Nair V et al. Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study. Clin Epigenetics. 2021;13(1):99. Published 2021 May 1. https:\/\/doi.org\/10.1186\/s13148-021-01081-x","DOI":"10.1186\/s13148-021-01081-x"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05030-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05030-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05030-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:48:23Z","timestamp":1777546103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05030-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5030"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05030-4","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript does not report on or involve the use of any primary animal or human data or tissue. The human cells iPS(IMR90)-4 were purchased from a commercial vendor (WiCell). The provider of the cell line has confirmed that informed consent has been obtained from the donor of the tissue from which the pluripotent stem cells have been derived (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}